6HESS G, ROSS P, GAMM H, et al. Molecular analysis of the erythropoietin receptor system in patients with polycythemia vera[J]. Br J Haematol, 1994,88: 794- 802.
7BROUDY V C, LIN N, BRICE M, NAKAMOTO B, et al. Erythropoietin receptor characteristics on primary human erythroid cells[J]. Blood, 1991, 77:2583- 2590.
8SPIVAK J L. Polycythemia vera: myths, mechanisms, and management[J]. Blood,2002,100:4272 -4290.
9JAMES C,UGO V,CASADEVALL N. et al. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects [J].Trends Mol Med,2005,11:546-554.
10LEVINE R L, GILLILAND G D. Myeloproliferative disorders [J]. Blood, 2008,112 : 2190 - 2198.
3Tefferi A,Thiele J,Orazi A. Proposals and rationale for revision of the World Health Organization diagnosis criteria for polycythemia vera,essential thrombocythemia.And primary myelofibrosis:recommendations from an ad hoc international expert panel[J].Blood,2007,(04):1092-1097.
4Aletaha D,Neogi T,Silman A I. 2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J].Annals of the Rheumatic Diseases,2010,(09):1580-1588.
5Levine R L,Gilliland D G. Myeloproliferative disorders[J].Blood,2008,(06):2190-2198.doi:10.1182/blood-2008-03-077966.
6Katchamart W,Trudeau J,Phumethum V. Efficacy and toxicity of methotrexate(MTX)monotherapy versus MTX combination therapy with non-biological disease modifying antirheumatic drugs in rheumatoid arthritis:a systematic review and meta-analysis[J].Annals of the Rheumatic Diseases,2009,(07):1105-1112.
